Clinical trials located in

Copenhagen

Copenhagen city is located in Denmark. Currently, 20 clinical trials are being conducted in this city.

Copenhagen, Denmark’s vibrant capital, is steeped in history and modern flair. Founded as a Viking fishing village in the 10th century, it boasts the distinction of hosting the world’s oldest monarchy. The city is renowned for its iconic Little Mermaid statue, honoring Hans Christian Andersen’s fairy tale. Copenhagen is a pioneer in sustainability, aiming to become the world’s first carbon-neutral capital by 2025. Its unique blend of ancient architecture and cutting-edge design, alongside extensive bike lanes, exemplifies a commitment to preserving the past while embracing the future.

  • CT-EU-00118673

    Study WVE-003 in patients with early-stage Huntington’s disease

    This clinical trial is a study designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of a new drug called WVE-003 in adult patients with early Huntington’s disease (HD). WVE-003 is a type of drug designed to target specific genetic sequences. In this case, it is targeting a single nucleotide polymorphism (SNP), known as SNP3, in Huntington’s disease patients. The drug is administered intrathecally, i.e., it is injected into the spinal canal.

    The study is double-blind, meaning neither patients nor researchers know who is receiving the actual drug and who is receiving the placebo. This helps ensure the results are impartial. The primary goal is to evaluate the safety of WVE-003 by monitoring the percentage of patients who experienced adverse events from day 1 to the end of the study, which lasts a minimum of 36 weeks.

    • WVE-003
  • Gene Therapy Trial for Limb-Girdle Muscular Dystrophy Type R9

    This here clinical trial is called the “GNT0006 Gene Therapy Trial in Patients With LGMDR9“. It’s a study to test the safety and effectiveness of a new gene therapy treatment for a rare muscle disease called LGMDR9, also known as limb-girdle muscular dystrophy type R9.

    The study has two main parts. In the first part, called Stage 1, a small group of patients will receive the gene therapy treatment at different dose levels to make sure it’s safe and to find the best dose. In the second part, called Stage 2, a larger group of 33 patients who can still walk will be split into two groups. One group will get the gene therapy treatment at the best dose found in Stage 1, and the other group will get a placebo, which is like a fake treatment. After one year, the groups will switch treatments.

    The main thing the researchers are looking at is how the gene therapy affects the patients’ lung function, measured by something called Forced Vital Capacity. They’ll be checking this at different time points up to one year after the treatment. The study will also look at whether the treatment is safe and how long the effects last, with patients being followed for up to 5 years after receiving the real gene therapy treatment.

    So in a nutshell, this is a clinical trial testing a new gene therapy for a rare muscle disease, with the main goal being to see if it can improve lung function and whether it’s safe for patients to take. The study will take several years to complete, but could lead to an important new treatment option for people with this condition.

  • Study of Pembrolizumab/Quavonlimab Combination vs Other Treatments for Colorectal Cancer

    This here clinical trial is aimin’ to take a good look at a new combination treatment called co-formulated pembrolizumab/quavonlimab for folks with stage IV colorectal cancer that’s got that microsatellite instability-high or mismatch repair deficient business goin’ on. The main goal is to see how well this new combo treatment works at shrinkin’ them tumors, compared to some other treatments out there.

    Now, the real important part is that the doctors’ll be keepin’ a close eye on how many folks get what they call an objective response, meanin’ their tumors either disappear completely or shrink down by at least 30%. They’ll be trackin’ this over a span of up to around 50 months to get a good picture of how effective this new treatment is.

    Safety’s always a top priority too, so the doctors’ll be watchin’ out for any side effects or issues that might crop up with this new combo treatment. It’s all about findin’ the best way to fight that cancer while keepin’ folks as comfortable as possible.

  • Study of the drug combination mRNA-4157/V940 and Pembrolizumab in the treatment of melanoma

    The aim of this clinical trial is to test whether a new drug called mRNA-4157/V940 in combination with pembrolizumab can help prevent the recurrence of melanoma in people who have already had it. Currently, mRNA-4157/V940 is what is called “individualized neoantigen therapy,” which means it is a therapy created specifically for each patient based on their cancer cells. Doctors give this drug along with pembrolizumab, a drug that helps the immune system fight cancer cells.

    The main goal of this study is to determine whether taking V940 and pembrolizumab together is more effective in preventing melanoma recurrence than taking pembrolizumab alone. Researchers will closely monitor how long it takes for the cancer to return or spread. The study will last for approximately 74 months.

    • mRNA-4157/V940
    • placebo
    • Pembrolizumab
  • Study on the effectiveness and safety of BBP-418 for Limb Girdle Muscular Dystrophy 2I patients

    This clinical trial is focused on a new treatment option for individuals diagnosed with Limb Girdle Muscular Dystrophy 2I (LGMD2I). This study is designed to explore the efficacy and safety of a medication called BBP-418 (Ribitol), which is administered as an oral solution. The medication is in the form of granules that are mixed with water to create a drinkable solution.

    The aim is to include participants aged 12 to 60 years old, covering a wide range of individuals affected by LGMD2I. Throughout a 36-month period, the study will closely monitor changes in the muscle function and overall health of the participants to determine the effectiveness and safety of BBP-418 in treating LGMD2I.

    A key aspect being observed is the change from baseline in the North Star Assessment for Limb Girdle Muscular Dystrophy after 36 months of treatment. This will aid in understanding the impact of BBP-418 on muscle function. In addition, the frequency and severity of any treatment-emergent adverse events will be tracked to ensure the medication’s safety over the long term.

    This study is a randomized, placebo-controlled, double-blind study, meaning participants will be randomly assigned to receive either the BBP-418 treatment or a placebo, with neither the participants nor the study staff aware of which group they are in. This approach helps ensure the reliability of the study results.

    • BBP-418 (ribitol)
  • Study of belzutifan for treating advanced cancers

    This clinical trial aim is to test out a new drug called belzutifan, also known as MK-6482 or WELIREG™. It’s a pill patient can take once a day, and the main goal is to see if it can shrink or get rid of tumors in folks with certain types of cancer.

    The cancers the researchers are looking at are pheochromocytoma and paraganglioma, which are tumors that start in the adrenal glands or nervous system. Pancreatic neuroendocrine tumors, tumors related to von Hippel-Lindau disease, advanced gastrointestinal stromal tumors, and other solid tumors with certain genetic changes that involve a protein called HIF-2α, there will be also tested.

    The big thing the researchers are  keeping an eye on is the objective response rate, which means how many folks see their tumors shrink or disappear completely while taking this drug. The researchers will be watching closely for any side effects too, of course, to make sure this new medicine is safe.

    • Belzutifan
  • Continued Parsaclisib treatment for B-cell cancer patients

    This is a phase II clinical trial focused on providing continuation of treatment with a drug called parsaclisib to people diagnosed with B-cell malignancies. The main goal of this study is to expand the treatment regimen established in the previous study. Study participants will receive parsaclisib as a stand-alone therapy (monotherapy) or in combination with other therapeutic agents, which may include itacitinib, ruxolitinib or ibrutinib. The study aims to facilitate participants’ ongoing care and contribute to the broader field of medical research by collecting data on the effectiveness and safety of prolonged use of parsaclisib.

    • Ibrutinib
    • Ruxolitinib
    • Itacitinib
    • Parsaclisib
  • Study of the effectiveness of a new drug in the treatment of heart failure and pulmonary hypertension

    This clinical trial explores the potential benefits of AZD3427 for individuals with heart failure (HF) and pulmonary hypertension (PH) Group 2, a condition characterized by increased blood pressure in the lungs due to heart disease. Around 220 participants will be randomly assigned to receive either AZD3427 or a placebo through subcutaneous injections every two weeks for 24 weeks. The trial aims to assess the impact of AZD3427 on reducing pulmonary vascular resistance (PVR) and improving various heart and lung health indicators. Participants will undergo multiple study visits, with the total duration of the study being approximately 32 to 37 weeks.

    • AZD3427- new potential medication for heart failure and pulmonary hypertension
  • Research on medicine combination for B-cell Non-Hodgkin Lymphoma

    This study is about testing epcoritamab, a new drug for a type of blood cancer called B-cell Non-Hodgkin Lymphoma. The goal is to see if the drug is safe for people and can successfully fight the cancer. Doctors will combine this drug with other medicines that are typically used to treat this cancer. The combined treatment will vary for different groups of patients, depending on factors like their specific type of cancer or their overall health. Some patients will be given epcoritamab on its own, while others will receive it with other cancer medicines. The study has two parts. The first part is to find a safe dose of the drug. The second part is to determine how well this drug helps in treating the cancer. Side effects will be closely monitored during the study.

    • etoposide phosphate
    • oxaliplatin
    • Prednisone
    • Dexamethasone
    • Carboplatin
    • Epcoritamab
    • Ifosfamide
    • Cytarabine
    • Gemcitabine
    • Cyclophosphamide
    • Vincristine
    • Doxorubicin
    • Bendamustine
    • Lenalidomide
    • Rituximab
  • Exploring treatment options for newly diagnosed Multiple Myeloma

    This clinical trial investigates two treatment paths for newly diagnosed multiple myeloma patients who are not planned for stem cell transplant initially. The first group receives a combination of bortezomib, lenalidomide, and dexamethasone (VRd) followed by cilta-cel, an innovative therapy. The second group receives VRd followed by continued treatment with lenalidomide and dexamethasone (Rd). The study evaluates the effectiveness of these treatments by monitoring disease progression, treatment response, and patient survival rates. It also assesses the safety and side effects of the treatments, aiming to improve the quality of life and outcomes for patients with multiple myeloma. The trial’s objective is to provide valuable data on the potential benefits of integrating cilta-cel in the treatment regimen, compared to the more traditional approach, offering insights for better management of this challenging cancer.

    • Cilta-cel
    • Fludarabine
    • Lenalidomide
    • Dexamethasone
    • Cyclophosphamide
    • Bortezomib
  • CT-EU-00041922

    Testing new medication for adult muscle inflammation treatment

    This study aims to test a medicine called Efgartigimod (EFG PH20 SC) for adults who are suffering from a disease called Idiopathic Inflammatory Myopathy (IIM), where muscles become inflamed for unknown reasons. This condition often falls into groups like dermatomyositis, immune-mediated necrotizing myopathy, or specific types of polymyositis. The trial wants to compare how good the medicine is against a placebo. The researchers will look at how much people’s symptoms improve and whether there are any side effects. The test is going to be carried out in many locations and will involve people over 18 years old.

    • Efgartigimod/ EFG PH20 SC
  • Testing golcadomide for safety & effectiveness in non-Hodgkin lymphomas

    This trial is about testing the safety and effectiveness of a drug called Golcadomide for people with a certain type of cancer called Non-Hodgkin Lymphomas that has come back or not responded to treatment. This drug can be taken by mouth and will be tested alone or together with other drugs used to treat lymphoma. It is for patients who tried at least two other treatments for their cancer, or if there arent suitable treatment for them. First, different doses of Golcadomide will be given to see which amount can be tolerated without causing too many side effects. Once that’s figured out, the trial will look at how well the chosen dose works either alone or with other lymphoma drugs. The researchersa will also study if eating food together with the drug will affect how the drug works and its safety.

    • Golcadomide/CC-99282
    • Valemetostat
    • Tafasitamab
    • Obinutuzumab
    • Rituximab
  • Exploring new potential treatment for advanced solid tumor patients

    This study is testing a drug named JDQ443 (Opnurasib) on patients with advanced kinds of tumors who also have a specific genetic mutation known as KRAS G12C. The purpose is to figure out how safe the drug is, how high a dose people can take without severe side effects, and how well the drug works to shrink the tumors. Patient’s reactions to the drug and any side effects researchers have will be carefully noted. Patients will get different amounts of the drug alone, a combination with other treatments (TNO155-Batoprotafib and Tislelizumab). Additionally, an assessment will be made regarding the peak concentration of the drug in the patient’s blood and the time it takes to reach that level. In patients receiving an additional drug, tislelizumab, testing will be conducted to determine whether this combination elicits any immune-related responses.

    • Batoprotafib/TNO155
    • Opnurasib/JDQ443
    • tislelizumab
  • Evaluating effects of pembrolizumab with chemotherapy and radiation for esophageal cancer

    This trial explores the impact of a drug called pembrolizumab on patients with a specific kind of cancer, Esophageal Carcinoma. It compares two treatments. Some patients will receive the standard treatment (chemotherapy and radiation), plus a placebo. Others will receive the standard treatment (chemotherapy and radiation) plus Pembrolizumab. The reason for doing it is to see if Pembrolizumab, when added to normal treatment, can help patients live without their cancer getting worse, or live longer overall. During the trial, patients will either be given pembrolizumab or placebo, as well as one of two chemotherapy combinations and radiation treatment, for about a year.

    • Pembrolizumab
    • levoleucovorin
    • leucovorin
    • 5-Fluorouracil
    • Cisplatin
    • Oxaliplatin
  • Study of alpelisib and fulvestrant for advanced breast cancer treatment

    This trial is looking at the effects of the combined use of two drugs, alpelisib and fulvestrant, in treating patients who have advanced breast cancer. The cancer should be HR-positive and HER2-negative, and have a specific mutation (PIK3CA). If the patients already underwent certain other treatments like CDK4/6 Inhibitors and aromatase Inhibitors, but the cancer has progressed, they could join this trial. Doctors will be able to compare the results of patients taking alpelisib and fulvestrant together, with those taking fulvestrant with a placebo, They aim to check which combination works better in delaying the advance of cancer or in improving a patient’s life duration.

    • Alpelisib
    • Fulvestrant
  • Comparing Imlifidase with standard treatment in anti-glomerular basement membrane disease

    This clinical trial is testing a medication called Imlifidase in patients who have a serious disease called anti-GBM (Goodpasture syndrome). The researchers are doing this study to compare two groups: people who take Imlifidase along with the usual treatment, and people who only get the usual treatment. This typical treatment consists of plasma exchange (PLEX), Cyclophosphamide and glucocorticoids. This study will last for 2 years. Researchers will measure things like kidney function, levels of harmful anti-GBM antibodies, breathing symptoms, drug interaction and patients’ quality of life.

    • Cyclophosphamide (CYC)
    • Glucocorticoids
    • Imlifidase
  • Testing new medication for advanced or spread-out solid tumors

    This research study is about checking if a new medicine, known as INCA33890, is safe for people who have advanced or metastatic solid tumors. This trial is important because it needs to be checked if this medicine can work safely without causing too much trouble or side effects for the person taking it. An important part of this trial is also to figure out how much of this medicine can be given safely to a person, so it helps to treat their cancer but doesn’t make them sick from the treatment itself.

    • INCA33890- new potential medication for solid tumors
  • Testing new medicine to treat acute Myeloid Leukemia that returns

    This study introduces AFM28, a potential treatment for Acute Myeloid Leukemia (AML) with certain characteristics (CD123-positive). It’s the first trial of its kind, focusing on finding the safest and most effective dosage. Participants will receive the medicine through an IV once a week. The study will closely watch how they respond to the treatment, including any side effects, to ensure the drug is safe and working as intended. This research is crucial for developing new treatments for AML.

    • AFM28-new medication for acute myeloid leukemia
  • Testing new potential therapy for safeness in treating solid tumors

    This clinical trial revolves around the investigation of a novel medication called GEN1047 and its application in individuals with various types of cancer. Given that this marks the initial utilization of GEN1047 in human subjects, the primary objective is to assess its safety and tolerability. The study aims to gather crucial insights into the optimal dosage and its impact on the human body. The trial is structured into two distinct phases. The initial phase involves a gradual escalation of GEN1047 doses, while the second phase focuses on testing the most effective dose identified during the initial phase. Throughout the study, any unfavorable changes in health associated with the study medication will be meticulously documented and analyzed. This comprehensive approach aims to ascertain both the safety profile and potential therapeutic efficacy of GEN1047 in the context of cancer treatment.

    • GEN1047

See more clinical trials in other cities in Denmark:

.